@article{75350ff8980e4a46829e9a1052b9888d,
title = "Evolving systemic management of urothelial cancers",
abstract = "Purpose of reviewBladder cancer is the 12th most common cancer worldwide. Historically, the systemic management of urothelial carcinoma has been confined to platinum-based chemotherapy. In this review, we discuss the evolving landscape of systemic treatment for urothelial carcinoma.Recent findingsSince 2016, when the Food and Drug Administration approved the first immune checkpoint inhibitor (CPI), programmed cell death 1 and programmed cell death ligand 1 inhibitors have been evaluated in the nonmuscle invasive bladder cancer, localized muscle invasive bladder cancer as well as advanced/metastatic bladder cancer settings. Newer approved treatments such as fibroblast growth factor receptor (FGFR) inhibitors and antibody-drug conjugates (ADCs) represent second-line and third-line options. These novel treatments are now being assessed in combination as well as with older traditional platinum-based chemotherapy.SummaryNovel therapies continue to improve bladder cancer outcomes. Personalized approach with well validated biomarkers are important to predict response to therapy.",
keywords = "antibody-drug conjugate, bladder cancer, checkpoint inhibitors, targeted therapy, urothelial carcinoma",
author = "Tan, {Wei Shen} and Tan, {Mae Yen} and Omar Alhalabi and Campbell, {Matthew T.} and Kamat, {Ashish M.} and Jianjun Gao",
note = "Funding Information: M.T.C. received research grants from Apricity Health, EMD Serono, Exelixis, Janssen, Pfizer and serves as a consultant to AstraZeneca, Astellas, Eisai, EMD Serono, Exelixis, Genentech, Pfizer, Seattle Genetics, AXDev, Exelixis and Pfizer. A.M.K. received grants from Adolor, BMS, FKD Industries, Heat Biologics, Janssen, Merck, Photocure, Seattle Genetics, Taris, and SWOG; is on the board of and receives consulting fees from Asieris, Astellas, Biological Dynamics, BMS, CG Oncology, H3 Biomedicine, Eisai, Engene, FerGene, Imagin Medical, Incyte DSMB, Janssen, Medac, Merck, Photocure, ProTara, Roche, Seattle Genetics, Sessen Bio, Theralase, TMC Innovation, US Biotest, and Urogen; has a joint patent for CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) with UT MD Anderson Cancer Center; and is the President of IBCG. J.J.G. serves as a consultant for ARMO Biosciences, AstraZeneca, Jounce, Nektar, and Pfizer. The other authors have nothing to disclose. Funding Information: O.A. is a recipient of a Young Investigator and a Career Development Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology. A.M.K. is supported by the Wayne B. Duddlesten Professorship in Cancer Research and the Raymond and Maria Floyd Bladder Cancer Research Foundation. J.J.G. is supported by the Doris Duke Clinical Scientist Development Award (#2018097), the MD Anderson Physician Scientist Award, Khalifa Physician Scientist Award, Andrew Sabin Family Foundation Fellows Award, MD Anderson Faculty Scholar Award, the David H. Koch Center for Applied Research of Genitourinary Cancers, Wendy and Leslie Irvin Barnhart Fund, Joan and Herb Kelleher Charitable Foundation, KCA Advanced Discovery Award, the Williams TNT Fund, the V Foundation Translational Award, the DOD KCRP Translational Research Partnership Award and NIH/NCI R01 CA254988-01A1. Publisher Copyright: {\textcopyright} 2023 Lippincott Williams and Wilkins. All rights reserved.",
year = "2023",
month = may,
day = "1",
doi = "10.1097/CCO.0000000000000942",
language = "English (US)",
volume = "35",
pages = "186--199",
journal = "Current opinion in oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "3",
}